Agenda – Day 2

Cahyani Endahayu is a Partner in the Mergers & Acquisitions Practice Group. Her work includes handling the corporate/licensing, compliance and day-to-day work of several of the Firm’s major clients and providing corporate, compliance and advisory support services to other clients in relation to corporate/commercial issues. She has advised a wide range of domestic and international clients across various industry sectors, including pharmaceutical and retail/trading. Cahyani’s experience includes the representation of various pharmaceutical companies and providing regulatory advice on investment, product registrations (including transfer of registration of drug products) and licensing requirements at the local authorities. Her past experience includes representing multi-national pharmaceutical manufacturing companies in areas of contracts, clinical/observational studies contracts/agreements, providing regulatory advice on product labelling, compliance with Indonesian anti-corruption law and antitrust related matters. She is a Member of the Indonesian Advocates Association (PERADI).

Yunjoh Lee is an attorney at Kim & Chang. She practices primarily in health and antitrust and competition.

Ms. Lee counsels multinational clients in the pharmaceutical, medical device and food industries on Korean regulatory compliance, corporate governance, competition law issues, and general corporate and commercial law matters. In particular, Ms. Lee counsels drug and device clients on various facets of anti-corruption compliance, such as designing and implementing effective compliance programs, employee training, monitoring, internal investigations, corrective action and remedial measures.

Her representative matters include representing pharmaceutical companies in investigations by the Korea Fair Trade Commission into alleged competition law violations relating to marketing and sales practices and defending pharmaceutical companies before the Korea Fair Trade Commission and the Ministry of Food & Drug Safety on charges of illegal interactions with healthcare professionals.

Eddie Chuah is a partner with the Dispute Resolution Practice Group, with experience in all aspects of civil litigation, arbitration, industrial relations disputes and compliance.

Eddie has undertaken a wide variety of briefs involving substantive law issues ranging from complex commercial transactions, insolvency litigation, shareholder disputes, construction, employment and administrative law. He also focuses on compliance issues, in particular, anti-corruption investigation, government procurement, audit and prevention.

Eddie regularly advises and assists both domestic and multinational corporations on a broad range of risk-related issues in compliance with both local and foreign authorities. His experience includes conducting internal investigations and audits, developing internal policies and procedures, as well as providing the necessary training to mitigate risks of fraud and corruption.

He has assisted and represented major corporations on external investigations by the Department of Justice and Securities Exchange Commission, the United Kingdom Serious Fraud Office, Singapore Corrupt Practices Investigation Bureau as well as the Malaysian Anti-Corruption Commission Agency.

Mr. Nguyen Xuan is the Chief of Compliance Officer (Vietnam/ Indochina) for Sanofi Aventis. Previously, he was the Head of Compliance at CHUBB Life Vietnam. He also held several roles at Metro Cash & Carry, including Head of Security, Audit and Compliance, Head of Security, Head of LPO and Compliance, Head of Audit & Local Program Office (LPO) and Head of Audit.

Maria Eugenia (Maru) Quindimil is currently APAC Ethics and Compliance Head for UCB. She handles an extensive geography, from Japan to India to Australia and leads the team of 20 people between direct and indirect reports. She is handling not only internal compliance processes but also third parties and alliance management for APAC. Previously, Maru was Senior Director APAC at GEC Risk Advisory LLC, and Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd. Throughout a career that has spanned 28 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.

Campbell Clark is Vice President, Legal and Compliance, Asia Pacific, for Medtronic, a healthcare company, and is based in Singapore. He was previously Chief Ethics & Compliance Officer, Asia Pacific, for Medtronic. Prior to Medtronic’s acquisition of Covidien in 2015, he was General Counsel, Asia, for Covidien. Campbell has also held senior roles in-house as an international legal counsel in Australia and Japan, and in private practice as a litigation lawyer in New Zealand and the United Kingdom. Since 2015 Campbell has been the Chair of the Legal/Ethics & Compliance Committee of the Asia Pacific Medical Technology Association (APACMed).

Jasmine Karimi has worked in law firms and MNCs in the US, UK, Canada, Hong Kong & Singapore, across diverse sectors (Media, Manufacturing, Luxury Goods and Biotech). Most recently, she was the Senior Director and Counsel, APAC for Illumina Inc. She is also part of APAC Management, Global Legal Management and leads the Women’s Leadership Network for the company in Singapore. She is admitted to practice law in England & Wales, Singapore, Canada, and Hong Kong. A firm believer in giving back, Jasmine has served on several boards and is the immediate past President of the Hong Kong Corporate Counsel Association (HKCCA). She currently sits on the SIAC Users Council. Jasmine has been named as one of the leading influential in-house lawyers in business in Asia in The Legal 500: Corporate Counsel 100 Asia 2014.

Michael Loucks is an experienced trial and appellate attorney whose practice focuses on internal investigations and government enforcement matters in the U.S. and abroad, and on false claims act litigation in federal and state courts. Prior to joining Skadden in 2010, Mr. Loucks served as acting U.S. attorney and first assistant U.S. attorney for the District of Massachusetts. He repeatedly has been selected for inclusion in Chambers USA: and The Best Lawyers in America.

Bob Pointer is a professional development and education professional specializing in the role and dynamics of humans in business and the link between security and productivity. Bob was a career detective with the City of London Police working primarily in the investigation of serious and organized crime. Following retirement from the Police service he took up a role as a lecturer at City -The University of London and was instrumental in the forming of the Centre for Security, Investigations and Police Sciences. During this time he provided Fraud investigation and prevention seminars on behalf of OLAF (the European Fraud Agency) in Romania, Bulgaria and Croatia. Additionally, he designed and delivered courses for the U.K. Serious Fraud Office, Medicines Agency and the Financial Ombudsman. Since 2011 he was worked as an independent consultant across 5 continents with many multi-national organizations.

Vanessa Han is the Compliance Director of Novo Nordisk (China) Pharmaceuticals Co., Ltd. Vanessa has more than 12 years of combined Finance, Internal Control and Legal & Compliance experience in the Pharm industry, she has worked at China, Denmark and the US for taking a wide range of responsibility on Compliance, financial management, audit and internal control. She is experienced with setting up corporate governance with compliance mechanism, actively working with industry committee as core member for shaping industry code of conduct. Vanessa holds a combined background of Law, Finance and Charted Certificated Accountant, UK.

Jonathan Shun Wah is Assistant General Counsel – Greater China and APAC Investigations Lead at Pfizer Inc, based in Hong Kong. Mr. Shun Wah is a qualified lawyer in Hong Kong and England & Wales. Prior to joining Pfizer, he worked in the Hong Kong offices of Orrick, Herrington & Sutcliffe and Dechert LLP. Mr. Shun Wah has been involved in FCPA and other internal investigations around Asia for the last nine years.

Angie Xenakis is a partner in Sidley Austin’s Singapore office, focusing primarily on internal investigations, government enforcement and compliance counseling. Before relocating to Singapore, Angie practiced in the firm’s Washington, D.C. office for fourteen years.

Angie has represented a wide variety of clients from across major industries, including pharmaceutical, medical devices, manufacturing, financial, defense, energy, consumer products and distribution. She has substantial experience advising multinational companies on all types of investigations and compliance matters under the U.S. Foreign Corrupt Practices Act (FCPA). She also has handled matters involving, among other things, healthcare fraud, securities fraud, false claims, accounting fraud, sanctions violations, anti-money laundering and insider trading. Angie has conducted numerous internal investigations throughout the U.S., as well as Asia, Europe, Africa, South America and the Middle East.

Ms. Yoo-kyung (Karen) Choi is Compliance Lead of Pfizer Korea. Prior to this, she assumed the role of Compliance Lead of Pfizer Japan. Karen provides proactive compliance advice and oversees compliance programs in line with domestic and international anti-bribery and corruption policies and laws. She also worked on various business development transactions in APAC region as a compliance counsel. She is a member of the Law Society of Upper Canada.

Justus is the Head of Legal & Compliance, ROPU SEASK At Boehringer Ingelheim Singapore Pte Ltd.

Katsumi Kojima is a Code Compliance Committee member of the Japan Pharmaceutical Manufacturers’ Association (JPMA) and serves as a leader of APEC Forum Taskforce. He has been working in the compliance field in both pharmaceutical and medical device industries for over 10 years and been a speaker and a panelist on various conferences, such as APEC Business Ethicsa for SMEs Forum (2014 – 2018), the Japan Society for Business Ethics (2017 and 2018), and the Waseda Medical Academic.

Carol Shi is a Compliance Director Asia Area and ANZ for AstraZeneca. She is a well-rounded finance and compliance professional with extensive international experience matched by proven leadership qualities.

She is recognized as a top performer with business acumen and a strong, disciplined approach, backed by skills and abilities honed in a wide range of challenging appointments within the Pharmaceutical, FMCG and Chemical Industries. Carol has operational experience in managing risks, change, organisational rationalisation as well as executing growth strategies.

Albert van Maaren is the Regional Compliance Officer Healthcare APAC (including China and Japan) for Merck KGaA. Albert has over 20 years of experience and achievements in the pharmaceutical field, including regulatory affairs, pharmacovigilance, quality assurance, market access, and compliance. Prior to his regional compliance role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal. Albert graduated with a Pharmaceutical degree from Utrecht University, the Netherlands, and completed his Executive Master of Compliance at VU University in Amsterdam (Compliance and Integrity Management).

Joyce Wong is Polaris’ Managing Director for Asia-Pacific, providing compliance technology and software solutions as well as insightful consulting and guidance to life science companies throughout the region to help companies solve their toughest compliance and transparency challenges. Joyce has more than 16 years’ experience in pharmaceutical industry, including a strong background in compliance and regulatory affairs, as well as project management, new product launch, strategic planning, marketing and business management. Prior to joining Polaris, Joyce served as General Manager for Eli Lilly Asia, Inc, responsible for managing the organization to deliver business results and achieve the highest standards across all areas of business.

Bob Pointer is a professional development and education professional specializing in the role and dynamics of humans in business and the link between security and productivity. Bob was a career detective with the City of London Police working primarily in the investigation of serious and organized crime. Following retirement from the Police service he took up a role as a lecturer at City -The University of London and was instrumental in the forming of the Centre for Security, Investigations and Police Sciences. During this time he provided Fraud investigation and prevention seminars on behalf of OLAF (the European Fraud Agency) in Romania, Bulgaria and Croatia. Additionally, he designed and delivered courses for the U.K. Serious Fraud Office, Medicines Agency and the Financial Ombudsman. Since 2011 he was worked as an independent consultant across 5 continents with many multi-national organizations.

Sasha Kalb is VP for Compliance & Risk, Asia Pacific, Global Partnerships & Alliances. On an interim basis, she is also responsible for EMEA. Sasha joined American Express Global Business Travel in November 2014 as Vice President for Compliance & Risk APAC. Prior to this role, Sasha worked at 3M, where she was the company’s first APAC Compliance Counsel and built a brand as a trusted advisor who helped leaders grow their businesses in a complaint and sustainable manner. She also served as the APAC Regional Compliance Counsel for Avon Products, Inc.

Albert van Maaren is the Regional Compliance Officer Healthcare APAC (including China and Japan) for Merck KGaA. Albert has over 20 years of experience and achievements in the pharmaceutical field, including regulatory affairs, pharmacovigilance, quality assurance, market access, and compliance. Prior to his regional compliance role in Singapore, Albert was also dedicated compliance officer for the Benelux countries and Portugal. Albert graduated with a Pharmaceutical degree from Utrecht University, the Netherlands, and completed his Executive Master of Compliance at VU University in Amsterdam (Compliance and Integrity Management).

Mr. Chi Chen is a technology partner in EY’s Forensic & Integrity Services (FIS) practice. He specializes in data compliance, IP and personal data privacy protection, predictive risk analytics, proactive compliance monitoring and management systems, fraud detection analytics, antitrust analytics, and eDiscovery. All of which require in-depth analysis of large, disparate sets of financial, operational and transactional data. Chi led his team to help clients identify high risk transactions or behaviors timely, efficiently, and effectively by leveraging advanced data analytics techniques including but not limited to data visualization, statistical modeling, text mining, and digital forensics. Chi has more than 15 years of combined advisory and audit experience in the United States, Australia and China. He has served many Fortune 500 and multinational companies in a variety of industries including pharmaceutical, medical devices, and healthcare.

Peter Andres is a Special Counsel in the Firm’s Compliance and Investigations practice group based in Hong Kong. Peter advises on a broad range of compliance matters, including due diligence, internal investigations, white collar criminal defense, and related civil litigation. He regularly handles business crimes investigations, with a focus on the U.S. Foreign Corrupt Practices Act (FCPA). Peter’s practice also involves advising on trade compliance issues that arise under US economic sanctions and export control laws. He advises on the extraterritorial application of these laws in cross border transactions, including mergers and acquisitions, joint venture arrangements, and other international commercial activities. Prior to joining the Hong Kong office, Peter worked in the Washington, D.C. and Sydney offices of the Firm. During his time in Washington, D.C., Peter spent significant time assisting in the representation of companies before the Department of Justice and the Securities and Exchange Commission on FCPA investigations.

Amy Huang is Director of Ethics & Compliance for Eli Lilly and Company (Lilly) at its China affiliate. Ms. Huang has over 21 years of experience in the Life Sciences industry, primarily in the many disciplines of finance, and now more recently in ethics and compliance. Her international experience spans across Asia and North America. After many years of leading different teams in the field of finance, she brings the rich combination of industry, finance, and leadership experiences to the field of ethics and compliance, where she has been a champion of evolving the role into a critical strategic business partner. Currently, she leads a team of compliance officers, who inform business ethical decision making through monitoring, CAPAs, and business risk advising.

As a Partner at Arnold & Porter, LLP, Keith Korenchuk counsels and advises global companies on regulatory and compliance matters worldwide, with a focus on compliance program effectiveness, compliance program implementation, operations and evaluation, and related regulatory counseling and advice. He works in a wide variety of industries and sectors including consumer products, electronics, energy, financial services, life sciences, medical device, pharmaceutical, and technology.

Since 2001, Mr. Korenchuk has been included in The Best Lawyers in America. He has developed, led, and implemented “hands-on” educational and healthcare programs that provide pharmaceuticals and healthcare services, teachers, school supplies, library resources, and computers to indigenous communities in South America for the past 12 years.

Maria Eugenia (Maru) Quindimil is currently APAC Ethics and Compliance Head for UCB. She handles an extensive geography, from Japan to India to Australia and leads the team of 20 people between direct and indirect reports. She is handling not only internal compliance processes but also third parties and alliance management for APAC. Previously, Maru was Senior Director APAC at GEC Risk Advisory LLC, and Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd. Throughout a career that has spanned 28 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct and active contributor in AP Compliance Network.

Mark Farrar is a Managing Director at Navigant and is the global leader of the Life Sciences Governance, Risk Management and Compliance Practice. Mark advises clients in the U.S., South America, Africa, Europe, and Asia on complex issues such as SEC financial accounting investigations, serving as the Independent Review Organization for those companies under a Corporate Integrity Agreement, preparing defense strategies for off-label allegations, anti-bribery and anti-corruption issues, pharmaceutical sales and marketing compliance, economic damages and lost profits settlement calculations, risk assessments, field force monitoring, transparency advisory services, data analytics, privacy compliance issues, and other various auditing and monitoring assessments. Mark served for over a year as the interim global Chief Compliance Officer for a large multi-billion-dollar medical device and diagnostics company with over 50 world-wide locations. He built the compliance program and established a global team, as well as implemented a comprehensive third party due diligence system to manage the anti-bribery/ anti-corruption risk of its distributors.

Bob Pointer is a professional development and education professional specializing in the role and dynamics of humans in business and the link between security and productivity. Bob was a career detective with the City of London Police working primarily in the investigation of serious and organized crime. Following retirement from the Police service he took up a role as a lecturer at City -The University of London and was instrumental in the forming of the Centre for Security, Investigations and Police Sciences. During this time he provided Fraud investigation and prevention seminars on behalf of OLAF (the European Fraud Agency) in Romania, Bulgaria and Croatia. Additionally, he designed and delivered courses for the U.K. Serious Fraud Office, Medicines Agency and the Financial Ombudsman. Since 2011 he was worked as an independent consultant across 5 continents with many multi-national organizations.

Uma Bhatt leads the Technology Solutions GTM at IQVIA for Asia based out of Singapore. She has extensive experience in Life Sciences and Healthcare vertical (R&D and IT) in Asia, providing strategic direction and thought leadership for solution approaches and implementation support across Clinical and Commercial businesses. Her expertise lies in product development and innovative solutions around AI, Big Data, patient support platforms, patient adherence solutions, compliance and quality solutions besides CRM and other commercial offerings. She’s also a trained Biostatistician and has extensive experience in Pharma, Medtech and Consumer Health R&D projects across multinationals in US, EU and Asia. As a General Manager, she has managed 140+ associates across the globe for engagements in USA, Germany, Netherlands, China and India in various pharma functions on the R&D side like Biometrics, Pharmacovigilance, Medical Writing etc. and on the commercial side around Sales and Marketing operations, Compliance and Quality solutions.

Shinji Iizumi is the Compliance Champion (Local Compliance Officer) of Ferring Pharmaceuticals, Tokyo, Japan. He is responsible for establishing the compliance framework and the function. He is also involved in activities of Japan Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry, and a member of governance, legal & compliance committee of EFPIA Japan. Beside compliance, he is also responsible for variety of non-commercial roles (e.g. ethics coordinator, business development, external affairs, public affairs, NHI price negotiator with the Authorities, internal business review process coordinator, contact person for Patient Groups, etc.) as the Director of Corporate Planning Office. Before joining Ferring, Shinji worked for Univ. of Pennsylvania (in U.S.A), Roche, Chugai, Fournier Pharma, Solvay Pharma, and GSK (in Japan). He is in the pharmaceutical industry for 30 years, and has had extensive experiences in medical research, commercial/marketing, medical affairs, external affairs, public relations, business development, general manager roles, etc.

Catherine Kanzler is Executive Director, Global Compliance Operations of Olympus Corporation of the Americas. She is responsible for building and harmonizing compliance programs throughout the Olympus Group worldwide. She manages the Company’s Corporate Integrity Agreement, and is a key contributor to the management of its Deferred Prosecution Agreements. Cathy was a leader in the design of the Company’s compliance monitoring, testing and data analytics programs, grants and distributor due diligence requirements, and Compliance, Grants and HIPAA governance committees. She is leading the implementation of the Company’s global Hotline system. Prior to joining Olympus, she practiced law in New York, representing a range of clients in corporate and commercial litigation.

Vanessa Han is the Compliance Director of Novo Nordisk (China) Pharmaceuticals Co., Ltd. Vanessa has more than 12 years of combined Finance, Internal Control and Legal & Compliance experience in the Pharm industry, she has worked at China, Denmark and the US for taking a wide range of responsibility on Compliance, financial management, audit and internal control. She is experienced with setting up corporate governance with compliance mechanism, actively working with industry committee as core member for shaping industry code of conduct. Vanessa holds a combined background of Law, Finance and Charted Certificated Accountant, UK.

Joyce Wong is Polaris’ Managing Director for Asia-Pacific, providing compliance technology and software solutions as well as insightful consulting and guidance to life science companies throughout the region to help companies solve their toughest compliance and transparency challenges. Joyce has more than 16 years’ experience in pharmaceutical industry, including a strong background in compliance and regulatory affairs, as well as project management, new product launch, strategic planning, marketing and business management. Prior to joining Polaris, Joyce served as General Manager for Eli Lilly Asia, Inc, responsible for managing the organization to deliver business results and achieve the highest standards across all areas of business.

Sasha Kalb is VP for Compliance & Risk, Asia Pacific, Global Partnerships & Alliances. On an interim basis, she is also responsible for EMEA. Sasha joined American Express Global Business Travel in November 2014 as Vice President for Compliance & Risk APAC. Prior to this role, Sasha worked at 3M, where she was the company’s first APAC Compliance Counsel and built a brand as a trusted advisor who helped leaders grow their businesses in a complaint and sustainable manner. She also served as the APAC Regional Compliance Counsel for Avon Products, Inc.

Haiyan Tang is a Litigation partner and the Chief Representative of the Paul Hastings Shanghai office. Ms. Tang’s practice focuses on global government enforcement proceedings, internal investigations, and dispute resolutions. Ms. Tang has advised numerous multinational companies on sensitive enforcement matters and internal investigations involving the Foreign Corrupt Practices Act, the Bribery Act, anticorruption regulations, healthcare programs, government sanctions, export control, business ethics requirements, securities laws, accounting/ bookkeeping standards, and other internal financial control.

Ms. Tang served as the Regional Director of a leading global pharmaceutical company while it was fulfilling its self-reporting obligation to the United States Department of Justice and the United States Securities and Exchange Commission. Ms. Tang also worked at the Silicon Valley office of a leading international law firm, representing multiple high-tech companies in U.S. intellectual property litigation.

Chris Fordham is a Partner in EY’s Forensic & Integrity Services team based in Hong Kong, where has lived for 20 years. During his many years working in the forensic accounting area, Chris has worked on a large number of forensic investigations dealing with fraud and corruption, including the US Foreign Corrupt Practices Act (FCPA), as well as being engaged on anti-money laundering risk consulting assignments, expect witness and general litigation support engagements, involving the preparation of reports for use in various disputes in both commercial and criminal cases.

Richard Kershaw is a partner in Deloitte’s Forensic practice, based in Shanghai. He specializes in technology strategies for complex investigations and disputes, and policy frameworks for information governance and security.

His primary focus is the financial services and life science sectors, and he also has experience assisting technology companies responding to litigation and regulatory enquiries. Prior to joining Deloitte in China, he served as the leader of Deloitte’s Forensic Technology team in Switzerland.

Prior to joining Deloitte, Richard led the forensic technology practice in Asia for a major disputes consultancy. He lived and worked in Japan and China for most of the last two decades, focused on crossborder, multi-language matters.

Vivian Robinson QC became a barrister in 1967 and practiced at the English criminal bar for over forty years, acting for both prosecution and defense. He sat as a part-time judge for over thirty years. He was appointed Queen’s Counsel in 1986, became Head of QEB Hollis Whiteman Chambers and served as Treasurer of Inner Temple.

He left the practicing law to take up appointment as first General Counsel at the Serious Fraud Office. In this capacity he played a prominent role in the development of the SFO’s enforcement strategy on the UK Bribery Act 2010 and was the SFO’s principal liaison with the business community on this subject.

He is a member of McGuireWoods’ Government Investigations & White-Collar Litigation team. He is a co-author of “The FCPA and UK Bribery Act – A Ready Reference for Business and Lawyers”, published by the American Bar Association.

Mini vandePol has been a Partner of Baker McKenzie for over 18 years. She was the Chair of the Global Compliance & Investigations Group securing a #4 ranking in the Top 30 Global Investigations Firms with GIR where she was also recognized as one of the “Top 100 Women in Investigations”. She currently leads the Baker Asia Compliance & Investigations Group focusing on compliance program enhancements, transactional compliance risk due diligence / post acquisition integration and internal or regulator led investigations. She has a deep understanding of the challenges faced by Healthcare clients throughout Asia having led significant multi-jurisdictional investigations in China, India, Vietnam and Bangladesh. Mini is the Baker representative on the World Economic Forum’s “Partnership Against Corruption” Initiative, is a member of the B20 Anti-Corruption Taskforce and the VP of the White Collar Women’s Defense Association (HK Chapter).

Bob Pointer is a professional development and education professional specializing in the role and dynamics of humans in business and the link between security and productivity. Bob was a career detective with the City of London Police working primarily in the investigation of serious and organized crime. Following retirement from the Police service he took up a role as a lecturer at City -The University of London and was instrumental in the forming of the Centre for Security, Investigations and Police Sciences. During this time he provided Fraud investigation and prevention seminars on behalf of OLAF (the European Fraud Agency) in Romania, Bulgaria and Croatia. Additionally, he designed and delivered courses for the U.K. Serious Fraud Office, Medicines Agency and the Financial Ombudsman. Since 2011 he was worked as an independent consultant across 5 continents with many multi-national organizations.